trending Market Intelligence /marketintelligence/en/news-insights/trending/B2NRD3Xrl5mShYi8-p3Ovw2 content esgSubNav
In This List

Flexion submits new drug application for osteoarthritis drug

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Flexion submits new drug application for osteoarthritis drug

Flexion Therapeutics Inc. submitted a new drug application to the U.S. Food and Drug Administration for its lead investigational product candidate Zilretta, which is being evaluated to treat patients with osteoarthritis of the knee.

Zilretta has also received a fast-track designation from the FDA.

The new drug application is supported by results from a phase 3 clinical trial, which showed a highly significant reduction in average daily pain versus placebo at week 12, with durable and clinically meaningful pain relief in patients with moderate to severe osteoarthritis knee pain.